Cardiopulmonary Disease Diagnostics and Treatment Market Size by Disease Type, Type, End User, Region – Revenue Pool Analysis, Margin Structure Assessment, Capital Flow Trends, Competitive Benchmarking & Forecast to 2032
4.67%
CAGR (2026-2032)
64.71 USD Bn.
Market Size
300
Report Pages
161
Market Tables
Overview
Global Cardiopulmonary Disease Diagnostics and Treatment Market size was valued at USD 61.82 Bn. in 2025 and the total revenue is expected to grow at 4.67% from 2026 to 2032, reaching nearly USD 85.1 Bn.
Cardiopulmonary Disease Diagnostics and Treatment Market Overview
The cardiopulmonary disease is the medical term used to define a range of serious disorders that affect the lungs “pulmonary” and heart “cardio”. The two main cardiopulmonary diseases due to tobacco are Chronic Obstructive Pulmonary Disorder (COPD) and Cardiovascular Disease (CVD).
To know about the Research Methodology:- Request Free Sample Report
Globally, more people die from cardiovascular diseases (CVDs) than from any other cause and a projected 17.5 Mn. people in 2012. Of these deaths, nearly 80% are because of heart attacks and strokes, and over three quarters occur in low- and middle-income (LMI) countries. In 2012-13, approximately 34% of cardiovascular diseases (CVDs) deaths occurred in people below 70 years of age. CVDs disproportionately affect LMICs, and in many economies, the economic and social burden is the highest between poor and lacking groups.
CVDs are mainly detected by using technologies like AI (artificial intelligence) in cardiovascular imaging and in IVD (vitro diagnostics) at point-of-care (POC). Artificial Intelligence in imaging is discussed before imaging in general as the imaging technologies available nowadays have not evolved significantly for many years.
Cardiopulmonary Disease Diagnostics and Treatment Market Segment Analysis
The MMR report covers all the technologies and trends that play a prominent role in the growth of the cardiopulmonary disease diagnostics and treatment market over 2025-2032. Recent trends in the treatment of cardiopulmonary disease revolve about cardiovascular tissue generation and cardiac rhythm management. Cardiac stents and valves are not mentioned at length because of the lack of developing technologies in some of the countries.
Based on type, the electrocardiogram (ECG) segment dominated the cardiopulmonary disease diagnostics and treatment market, with a market size of USD xxMn. in 2022 and to reach US$ xxMn. by 2029, with a CAGR of xx.10%. This is attributed to the growing adoption of POC testing devices and mounting aging population. Also, the report covers the segments in the market such as dosage, application, and end-user.
Regional Insights
North America accounted for the largest cardiopulmonary disease diagnostics and treatment market share in 2022, with a market value of USD xx Mn; the regional market is expected to register a CAGR of 40% during 2025-2032. The major reasons for this growth are changing the lifestyle, growing awareness of many heart diseases in the USA.
Europe accounts for the second-highest revenue share contribution to the cardiopulmonary disease diagnostics and treatment market owing to the upsurge in heart rhythm problems, diabetes and increase in the elderly population.
The CVDs establish the leading cause of deaths in France, accounting for nearly 27% of the 535,000 deaths in 2011-12. Therefore, the growing prevalence of CVDs is likely to contribute to the growth of the market in France.
The objective of the report is to present a comprehensive analysis of the Global Cardiopulmonary Disease Diagnostics and Treatment Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.
The report also helps in understanding Global Cardiopulmonary Disease Diagnostics and Treatment Market dynamics, structure by analyzing the market segments and projects the Global market size. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global market make the report investor’s guide.
Cardiopulmonary Disease Diagnostics and Treatment Market Scope: Inquire before buying
| Cardiopulmonary Disease Diagnostics and Treatment Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2025 | Forecast Period: | 2026-2032 |
| Historical Data: | 2020 to 2025 | Market Size in 2025: | 61.82 USD Bn |
| Forecast Period 2026-2032 CAGR: | 4.67% | Market Size in 2032: | 85.1 USD Bn |
| Segments Covered: | by Disease Type | Cardiovascular diseases Coronary artery disease Angina pectoris Myocardial infarction Dysrhythmia Hypertension Others Respiratory diseases Influenza Asthma Bronchitis |
|
| by Type | Diagnostics Electrocardiogram (ECG) Holter monitoring Echocardiogram Stress test Cardiac catheterization Cardiac computerized tomography (CT) scan Cardiac magnetic resonance imaging (MRI) Single-photon emission computed tomography (SPECT) Stress blood pressure monitors Pulse oximeters Spirometry Treatment Medication |
||
| by End User | Hospitals Clinics Diagnostic centers Specialty Clinics and Rehab Centers Research Institutes Others |
||
| by Device Type | Diagnostic and Monitoring Devices Therapeutic And Surgical Devices |
||
Cardiopulmonary Disease Diagnostics and Treatment Market, by Region
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
North America (United States, Canada and Mexico)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)
Key Player / Competitors Profile Covered in Cardiopulmonary Disease Diagnostics and Treatment Market Report in Strategic Perspective:
Cardinal Health
Cosmed Medical
GE Healthcare
Halma plc
Hill-Rom Holdings, Inc.
Koninklijke Philips N.V. (Philips Healthcare)
MGC Diagnostics Corporation
NIHON KOHDEN CORPORATION
Schiller AG
Masimo Corporation
Vyaire Medical Inc.
Medtronic PLC
Boston Scientific Corporation
LivaNova PLC
Siemens Healthcare / Siemens Healthineers
St. Jude Medical, Inc.
Stryker Corporation
Baxter International Inc.
Abbott Laboratories
Becton Dickinson (BD)
Table of Contents
Global Cardiopulmonary Disease Diagnostics and Treatment Market
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
1.3. Research Objectives
2. Assumptions and Research Methodology
2.1. Report Assumptions
2.2. Abbreviations
2.3. Research Methodology
2.3.1. Secondary Research
2.3.1.1. Secondary data
2.3.1.2. Secondary Sources
2.3.2. Primary Research
2.3.2.1. Data from Primary Sources
2.3.2.2. Breakdown of Primary Sources
3. Executive Summary: Global Cardiopulmonary Disease Diagnostics and Treatment Market Size, by Market Value (US$ Bn)
4. Market Overview
4.1. Introduction
4.2. Market Indicator
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Porter’s Analysis
4.4. Value Chain Analysis
4.5. Market Risk Analysis
4.6. SWOT Analysis
4.7. Industry Trends and Emerging Technologies
5. Supply Side and Demand Side Indicators
6. Global Cardiopulmonary Disease Diagnostics and Treatment Market Analysis and Forecast
6.1. Cardiopulmonary Disease Diagnostics and Treatment Market Size & Y-o-Y Growth Analysis
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Middle East & Africa
6.1.5. South America
7. Global Cardiopulmonary Disease Diagnostics and Treatment Market Analysis and Forecast, By Type
7.1. Introduction and Definition
7.2. Key Findings
7.3. Cardiopulmonary Disease Diagnostics and Treatment Market Value Share Analysis, By Type
7.4. Cardiopulmonary Disease Diagnostics and Treatment Market Size (US$ Bn) Forecast, By Type
7.5. Cardiopulmonary Disease Diagnostics and Treatment Market Analysis, By Type
7.6. Cardiopulmonary Disease Diagnostics and Treatment Market Attractiveness Analysis, By Type
8. Global Cardiopulmonary Disease Diagnostics and Treatment Market Analysis and Forecast, By Disease Type
8.1. Introduction and Definition
8.2. Key Findings
8.3. Cardiopulmonary Disease Diagnostics and Treatment Market Value Share Analysis, By Disease Type
8.4. Cardiopulmonary Disease Diagnostics and Treatment Market Size (US$ Bn) Forecast, By Disease Type
8.5. Cardiopulmonary Disease Diagnostics and Treatment Market Analysis, By Disease Type
8.6. Cardiopulmonary Disease Diagnostics and Treatment Market Attractiveness Analysis, By Disease Type
9. Global Cardiopulmonary Disease Diagnostics and Treatment Market Analysis and Forecast, By End User
9.1. Introduction and Definition
9.2. Key Findings
9.3. Cardiopulmonary Disease Diagnostics and Treatment Market Value Share Analysis, By End User
9.4. Cardiopulmonary Disease Diagnostics and Treatment Market Size (US$ Bn) Forecast, By End User
9.5. Cardiopulmonary Disease Diagnostics and Treatment Market Analysis, By End User
9.6. Cardiopulmonary Disease Diagnostics and Treatment Market Attractiveness Analysis, By End User
10. Global Cardiopulmonary Disease Diagnostics and Treatment Market Analysis, by Region
10.1. Cardiopulmonary Disease Diagnostics and Treatment Market Value Share Analysis, by Region
10.2. Cardiopulmonary Disease Diagnostics and Treatment Market Size (US$ Bn) Forecast, by Region
10.3. Cardiopulmonary Disease Diagnostics and Treatment Market Attractiveness Analysis, by Region
11. North America Cardiopulmonary Disease Diagnostics and Treatment Market Analysis
11.1. Key Findings
11.2. North America Cardiopulmonary Disease Diagnostics and Treatment Market Overview
11.3. North America Cardiopulmonary Disease Diagnostics and Treatment Market Value Share Analysis, By Type
11.4. North America Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By Type
11.4.1. Diagnostics
11.4.1.1. Electrocardiogram (ECG)
11.4.1.2. Holter monitoring
11.4.1.3. Echocardiogram
11.4.1.4. Stress test
11.4.1.5. Cardiac catheterization
11.4.1.6. Cardiac computerized tomography (CT) scan
11.4.1.7. Cardiac magnetic resonance imaging (MRI)
11.4.1.8. Single-photon emission computed tomography (SPECT)
11.4.1.9. Stress blood pressure monitors
11.4.1.10. Pulse oximeters
11.4.1.11. Spirometry
11.4.1.12. Treatment
11.4.2. Medication
11.4.2.1. Angiotensin-converting enzyme (ACE) inhibitors
11.4.2.2. Angiotensin II receptor blockers (ARBS)
11.4.2.3. Anticoagulants
11.4.2.4. Antiplatelet agents
11.4.2.5. Others
11.5. North America Cardiopulmonary Disease Diagnostics and Treatment Market Value Share Analysis, By Disease Type
11.6. North America Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By Disease Type
11.6.1. Cardiovascular diseases
11.6.1.1. Coronary artery disease
11.6.1.2. Angina pectoris
11.6.1.3. Myocardial infarction
11.6.1.4. Dysrhythmia
11.6.1.5. Hypertension
11.6.1.6. Others
11.6.2. Respiratory diseases
11.6.2.1. Influenza
11.6.2.2. Asthma
11.6.2.3. Bronchitis
11.6.2.4. Emphysema
11.6.2.5. Cystic fibrosis
11.6.2.6. Others
11.7. North America Cardiopulmonary Disease Diagnostics and Treatment Market Value Share Analysis, By End User
11.8. North America Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By End User
11.8.1. Hospitals
11.8.2. Clinics
11.8.3. Diagnostic centers
11.8.4. Specialty Clinics and Rehab Centers
11.8.5. Research Institutes
11.8.6. Others
11.9. North America Cardiopulmonary Disease Diagnostics and Treatment Market Value Share Analysis, by Country
11.10. North America Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, by Country
11.10.1. U.S.
11.10.2. Canada
11.11. North America Cardiopulmonary Disease Diagnostics and Treatment Market Analysis, by Country
11.12. U.S. Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By Type
11.12.1. Diagnostics
11.12.1.1. Electrocardiogram (ECG)
11.12.1.2. Holter monitoring
11.12.1.3. Echocardiogram
11.12.1.4. Stress test
11.12.1.5. Cardiac catheterization
11.12.1.6. Cardiac computerized tomography (CT) scan
11.12.1.7. Cardiac magnetic resonance imaging (MRI)
11.12.1.8. Single-photon emission computed tomography (SPECT)
11.12.1.9. Stress blood pressure monitors
11.12.1.10. Pulse oximeters
11.12.1.11. Spirometry
11.12.1.12. Treatment
11.12.2. Medication
11.12.2.1. Angiotensin-converting enzyme (ACE) inhibitors
11.12.2.2. Angiotensin II receptor blockers (ARBS)
11.12.2.3. Anticoagulants
11.12.2.4. Antiplatelet agents
11.12.2.5. Others
11.13. U.S. Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By Disease Type
11.13.1. Cardiovascular diseases
11.13.1.1. Coronary artery disease
11.13.1.2. Angina pectoris
11.13.1.3. Myocardial infarction
11.13.1.4. Dysrhythmia
11.13.1.5. Hypertension
11.13.1.6. Others
11.13.2. Respiratory diseases
11.13.2.1. Influenza
11.13.2.2. Asthma
11.13.2.3. Bronchitis
11.13.2.4. Emphysema
11.13.2.5. Cystic fibrosis
11.13.2.6. Others
11.14. U.S. Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By End User
11.14.1. Hospitals
11.14.2. Clinics
11.14.3. Diagnostic centers
11.14.4. Specialty Clinics and Rehab Centers
11.14.5. Research Institutes
11.14.6. Others
11.15. Canada Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By Type
11.15.1. Diagnostics
11.15.1.1. Electrocardiogram (ECG)
11.15.1.2. Holter monitoring
11.15.1.3. Echocardiogram
11.15.1.4. Stress test
11.15.1.5. Cardiac catheterization
11.15.1.6. Cardiac computerized tomography (CT) scan
11.15.1.7. Cardiac magnetic resonance imaging (MRI)
11.15.1.8. Single-photon emission computed tomography (SPECT)
11.15.1.9. Stress blood pressure monitors
11.15.1.10. Pulse oximeters
11.15.1.11. Spirometry
11.15.1.12. Treatment
11.15.2. Medication
11.15.2.1. Angiotensin-converting enzyme (ACE) inhibitors
11.15.2.2. Angiotensin II receptor blockers (ARBS)
11.15.2.3. Anticoagulants
11.15.2.4. Antiplatelet agents
11.15.2.5. Others
11.16. Canada Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By Disease Type
11.16.1. Cardiovascular diseases
11.16.1.1. Coronary artery disease
11.16.1.2. Angina pectoris
11.16.1.3. Myocardial infarction
11.16.1.4. Dysrhythmia
11.16.1.5. Hypertension
11.16.1.6. Others
11.16.2. Respiratory diseases
11.16.2.1. Influenza
11.16.2.2. Asthma
11.16.2.3. Bronchitis
11.16.2.4. Emphysema
11.16.2.5. Cystic fibrosis
11.16.2.6. Others
11.17. Canada Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By End User
11.17.1. Hospitals
11.17.2. Clinics
11.17.3. Diagnostic centers
11.17.4. Specialty Clinics and Rehab Centers
11.17.5. Research Institutes
11.17.6. Others
11.18. North America Cardiopulmonary Disease Diagnostics and Treatment Market Attractiveness Analysis
11.18.1. By Type
11.18.2. By Disease Type
11.18.3. By End User
11.19. PEST Analysis
11.20. Key Trends
11.21. Key Developments
12. Europe Cardiopulmonary Disease Diagnostics and Treatment Market Analysis
12.1. Key Findings
12.2. Europe Cardiopulmonary Disease Diagnostics and Treatment Market Overview
12.3. Europe Cardiopulmonary Disease Diagnostics and Treatment Market Value Share Analysis, By Type
12.4. Europe Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By Type
12.4.1. Diagnostics
12.4.1.1. Electrocardiogram (ECG)
12.4.1.2. Holter monitoring
12.4.1.3. Echocardiogram
12.4.1.4. Stress test
12.4.1.5. Cardiac catheterization
12.4.1.6. Cardiac computerized tomography (CT) scan
12.4.1.7. Cardiac magnetic resonance imaging (MRI)
12.4.1.8. Single-photon emission computed tomography (SPECT)
12.4.1.9. Stress blood pressure monitors
12.4.1.10. Pulse oximeters
12.4.1.11. Spirometry
12.4.1.12. Treatment
12.4.2. Medication
12.4.2.1. Angiotensin-converting enzyme (ACE) inhibitors
12.4.2.2. Angiotensin II receptor blockers (ARBS)
12.4.2.3. Anticoagulants
12.4.2.4. Antiplatelet agents
12.4.2.5. Others
12.5. Europe Cardiopulmonary Disease Diagnostics and Treatment Market Value Share Analysis, By Disease Type
12.6. Europe Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By Disease Type
12.6.1. Cardiovascular diseases
12.6.1.1. Coronary artery disease
12.6.1.2. Angina pectoris
12.6.1.3. Myocardial infarction
12.6.1.4. Dysrhythmia
12.6.1.5. Hypertension
12.6.1.6. Others
12.6.2. Respiratory diseases
12.6.2.1. Influenza
12.6.2.2. Asthma
12.6.2.3. Bronchitis
12.6.2.4. Emphysema
12.6.2.5. Cystic fibrosis
12.6.2.6. Others
12.7. Europe Cardiopulmonary Disease Diagnostics and Treatment Market Value Share Analysis, By End User
12.8. Europe Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By End User
12.8.1. Hospitals
12.8.2. Clinics
12.8.3. Diagnostic centers
12.8.4. Specialty Clinics and Rehab Centers
12.8.5. Research Institutes
12.8.6. Others
12.9. Europe Cardiopulmonary Disease Diagnostics and Treatment Market Value Share Analysis, by Country
12.10. Europe Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, by Country
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Europe Cardiopulmonary Disease Diagnostics and Treatment Market Analysis, by Country
12.12. Germany Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By Type
12.12.1. Diagnostics
12.12.1.1. Electrocardiogram (ECG)
12.12.1.2. Holter monitoring
12.12.1.3. Echocardiogram
12.12.1.4. Stress test
12.12.1.5. Cardiac catheterization
12.12.1.6. Cardiac computerized tomography (CT) scan
12.12.1.7. Cardiac magnetic resonance imaging (MRI)
12.12.1.8. Single-photon emission computed tomography (SPECT)
12.12.1.9. Stress blood pressure monitors
12.12.1.10. Pulse oximeters
12.12.1.11. Spirometry
12.12.1.12. Treatment
12.12.2. Medication
12.12.2.1. Angiotensin-converting enzyme (ACE) inhibitors
12.12.2.2. Angiotensin II receptor blockers (ARBS)
12.12.2.3. Anticoagulants
12.12.2.4. Antiplatelet agents
12.12.2.5. Others
12.13. Germany Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By Disease Type
12.13.1. Cardiovascular diseases
12.13.1.1. Coronary artery disease
12.13.1.2. Angina pectoris
12.13.1.3. Myocardial infarction
12.13.1.4. Dysrhythmia
12.13.1.5. Hypertension
12.13.1.6. Others
12.13.2. Respiratory diseases
12.13.2.1. Influenza
12.13.2.2. Asthma
12.13.2.3. Bronchitis
12.13.2.4. Emphysema
12.13.2.5. Cystic fibrosis
12.13.2.6. Others
12.14. Germany Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By End User
12.14.1. Hospitals
12.14.2. Clinics
12.14.3. Diagnostic centers
12.14.4. Specialty Clinics and Rehab Centers
12.14.5. Research Institutes
12.14.6. Others
12.15. U.K. Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By Type
12.15.1. Diagnostics
12.15.1.1. Electrocardiogram (ECG)
12.15.1.2. Holter monitoring
12.15.1.3. Echocardiogram
12.15.1.4. Stress test
12.15.1.5. Cardiac catheterization
12.15.1.6. Cardiac computerized tomography (CT) scan
12.15.1.7. Cardiac magnetic resonance imaging (MRI)
12.15.1.8. Single-photon emission computed tomography (SPECT)
12.15.1.9. Stress blood pressure monitors
12.15.1.10. Pulse oximeters
12.15.1.11. Spirometry
12.15.1.12. Treatment
12.15.2. Medication
12.15.2.1. Angiotensin-converting enzyme (ACE) inhibitors
12.15.2.2. Angiotensin II receptor blockers (ARBS)
12.15.2.3. Anticoagulants
12.15.2.4. Antiplatelet agents
12.15.2.5. Others
12.16. U.K. Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By Disease Type
12.16.1. Cardiovascular diseases
12.16.1.1. Coronary artery disease
12.16.1.2. Angina pectoris
12.16.1.3. Myocardial infarction
12.16.1.4. Dysrhythmia
12.16.1.5. Hypertension
12.16.1.6. Others
12.16.2. Respiratory diseases
12.16.2.1. Influenza
12.16.2.2. Asthma
12.16.2.3. Bronchitis
12.16.2.4. Emphysema
12.16.2.5. Cystic fibrosis
12.16.2.6. Others
12.17. U.K. Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By End User
12.17.1. Hospitals
12.17.2. Clinics
12.17.3. Diagnostic centers
12.17.4. Specialty Clinics and Rehab Centers
12.17.5. Research Institutes
12.17.6. Others
12.18. France Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By Type
12.18.1. Diagnostics
12.18.1.1. Electrocardiogram (ECG)
12.18.1.2. Holter monitoring
12.18.1.3. Echocardiogram
12.18.1.4. Stress test
12.18.1.5. Cardiac catheterization
12.18.1.6. Cardiac computerized tomography (CT) scan
12.18.1.7. Cardiac magnetic resonance imaging (MRI)
12.18.1.8. Single-photon emission computed tomography (SPECT)
12.18.1.9. Stress blood pressure monitors
12.18.1.10. Pulse oximeters
12.18.1.11. Spirometry
12.18.1.12. Treatment
12.18.2. Medication
12.18.2.1. Angiotensin-converting enzyme (ACE) inhibitors
12.18.2.2. Angiotensin II receptor blockers (ARBS)
12.18.2.3. Anticoagulants
12.18.2.4. Antiplatelet agents
12.18.2.5. Others
12.19. France Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By Disease Type
12.19.1. Cardiovascular diseases
12.19.1.1. Coronary artery disease
12.19.1.2. Angina pectoris
12.19.1.3. Myocardial infarction
12.19.1.4. Dysrhythmia
12.19.1.5. Hypertension
12.19.1.6. Others
12.19.2. Respiratory diseases
12.19.2.1. Influenza
12.19.2.2. Asthma
12.19.2.3. Bronchitis
12.19.2.4. Emphysema
12.19.2.5. Cystic fibrosis
12.19.2.6. Others
12.20. France Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By End User
12.20.1. Hospitals
12.20.2. Clinics
12.20.3. Diagnostic centers
12.20.4. Specialty Clinics and Rehab Centers
12.20.5. Research Institutes
12.20.6. Others
12.21. Italy Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By Type
12.21.1. Diagnostics
12.21.1.1. Electrocardiogram (ECG)
12.21.1.2. Holter monitoring
12.21.1.3. Echocardiogram
12.21.1.4. Stress test
12.21.1.5. Cardiac catheterization
12.21.1.6. Cardiac computerized tomography (CT) scan
12.21.1.7. Cardiac magnetic resonance imaging (MRI)
12.21.1.8. Single-photon emission computed tomography (SPECT)
12.21.1.9. Stress blood pressure monitors
12.21.1.10. Pulse oximeters
12.21.1.11. Spirometry
12.21.1.12. Treatment
12.21.2. Medication
12.21.2.1. Angiotensin-converting enzyme (ACE) inhibitors
12.21.2.2. Angiotensin II receptor blockers (ARBS)
12.21.2.3. Anticoagulants
12.21.2.4. Antiplatelet agents
12.21.2.5. Others
12.22. Italy Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By Disease Type
12.22.1. Cardiovascular diseases
12.22.1.1. Coronary artery disease
12.22.1.2. Angina pectoris
12.22.1.3. Myocardial infarction
12.22.1.4. Dysrhythmia
12.22.1.5. Hypertension
12.22.1.6. Others
12.22.2. Respiratory diseases
12.22.2.1. Influenza
12.22.2.2. Asthma
12.22.2.3. Bronchitis
12.22.2.4. Emphysema
12.22.2.5. Cystic fibrosis
12.22.2.6. Others
12.23. Italy Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By End User
12.23.1. Hospitals
12.23.2. Clinics
12.23.3. Diagnostic centers
12.23.4. Specialty Clinics and Rehab Centers
12.23.5. Research Institutes
12.23.6. Others
12.24. Spain Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By Type
12.24.1. Diagnostics
12.24.1.1. Electrocardiogram (ECG)
12.24.1.2. Holter monitoring
12.24.1.3. Echocardiogram
12.24.1.4. Stress test
12.24.1.5. Cardiac catheterization
12.24.1.6. Cardiac computerized tomography (CT) scan
12.24.1.7. Cardiac magnetic resonance imaging (MRI)
12.24.1.8. Single-photon emission computed tomography (SPECT)
12.24.1.9. Stress blood pressure monitors
12.24.1.10. Pulse oximeters
12.24.1.11. Spirometry
12.24.1.12. Treatment
12.24.2. Medication
12.24.2.1. Angiotensin-converting enzyme (ACE) inhibitors
12.24.2.2. Angiotensin II receptor blockers (ARBS)
12.24.2.3. Anticoagulants
12.24.2.4. Antiplatelet agents
12.24.2.5. Others
12.25. Spain Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By Disease Type
12.25.1. Cardiovascular diseases
12.25.1.1. Coronary artery disease
12.25.1.2. Angina pectoris
12.25.1.3. Myocardial infarction
12.25.1.4. Dysrhythmia
12.25.1.5. Hypertension
12.25.1.6. Others
12.25.2. Respiratory diseases
12.25.2.1. Influenza
12.25.2.2. Asthma
12.25.2.3. Bronchitis
12.25.2.4. Emphysema
12.25.2.5. Cystic fibrosis
12.25.2.6. Others
12.26. Spain Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By End User
12.26.1. Hospitals
12.26.2. Clinics
12.26.3. Diagnostic centers
12.26.4. Specialty Clinics and Rehab Centers
12.26.5. Research Institutes
12.26.6. Others
12.27. Rest of Europe Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By Type
12.27.1. Diagnostics
12.27.1.1. Electrocardiogram (ECG)
12.27.1.2. Holter monitoring
12.27.1.3. Echocardiogram
12.27.1.4. Stress test
12.27.1.5. Cardiac catheterization
12.27.1.6. Cardiac computerized tomography (CT) scan
12.27.1.7. Cardiac magnetic resonance imaging (MRI)
12.27.1.8. Single-photon emission computed tomography (SPECT)
12.27.1.9. Stress blood pressure monitors
12.27.1.10. Pulse oximeters
12.27.1.11. Spirometry
12.27.1.12. Treatment
12.27.2. Medication
12.27.2.1. Angiotensin-converting enzyme (ACE) inhibitors
12.27.2.2. Angiotensin II receptor blockers (ARBS)
12.27.2.3. Anticoagulants
12.27.2.4. Antiplatelet agents
12.27.2.5. Others
12.28. Rest of Europe Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By Disease Type
12.28.1. Cardiovascular diseases
12.28.1.1. Coronary artery disease
12.28.1.2. Angina pectoris
12.28.1.3. Myocardial infarction
12.28.1.4. Dysrhythmia
12.28.1.5. Hypertension
12.28.1.6. Others
12.28.2. Respiratory diseases
12.28.2.1. Influenza
12.28.2.2. Asthma
12.28.2.3. Bronchitis
12.28.2.4. Emphysema
12.28.2.5. Cystic fibrosis
12.28.2.6. Others
12.29. Rest Of Europe Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By End User
12.29.1. Hospitals
12.29.2. Clinics
12.29.3. Diagnostic centers
12.29.4. Specialty Clinics and Rehab Centers
12.29.5. Research Institutes
12.29.6. Others
12.30. Europe Cardiopulmonary Disease Diagnostics and Treatment Market Attractiveness Analysis
12.30.1. By Type
12.30.2. By Disease Type
12.30.3. By End User
12.31. PEST Analysis
12.32. Key Trends
12.33. Key Developments
13. Asia Pacific Cardiopulmonary Disease Diagnostics and Treatment Market Analysis
13.1. Key Findings
13.2. Asia Pacific Cardiopulmonary Disease Diagnostics and Treatment Market Overview
13.3. Asia Pacific Cardiopulmonary Disease Diagnostics and Treatment Market Value Share Analysis, By Type
13.4. Asia Pacific Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By Type
13.4.1. Diagnostics
13.4.1.1. Electrocardiogram (ECG)
13.4.1.2. Holter monitoring
13.4.1.3. Echocardiogram
13.4.1.4. Stress test
13.4.1.5. Cardiac catheterization
13.4.1.6. Cardiac computerized tomography (CT) scan
13.4.1.7. Cardiac magnetic resonance imaging (MRI)
13.4.1.8. Single-photon emission computed tomography (SPECT)
13.4.1.9. Stress blood pressure monitors
13.4.1.10. Pulse oximeters
13.4.1.11. Spirometry
13.4.1.12. Treatment
13.4.2. Medication
13.4.2.1. Angiotensin-converting enzyme (ACE) inhibitors
13.4.2.2. Angiotensin II receptor blockers (ARBS)
13.4.2.3. Anticoagulants
13.4.2.4. Antiplatelet agents
13.4.2.5. Others
13.5. Asia Pacific Cardiopulmonary Disease Diagnostics and Treatment Market Value Share Analysis, By Disease Type
13.6. Asia Pacific Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By Disease Type
13.6.1. Cardiovascular diseases
13.6.1.1. Coronary artery disease
13.6.1.2. Angina pectoris
13.6.1.3. Myocardial infarction
13.6.1.4. Dysrhythmia
13.6.1.5. Hypertension
13.6.1.6. Others
13.6.2. Respiratory diseases
13.6.2.1. Influenza
13.6.2.2. Asthma
13.6.2.3. Bronchitis
13.6.2.4. Emphysema
13.6.2.5. Cystic fibrosis
13.6.2.6. Others
13.7. Asia Pacific Cardiopulmonary Disease Diagnostics and Treatment Market Value Share Analysis, By End User
13.8. Asia Pacific Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By End User
13.8.1. Hospitals
13.8.2. Clinics
13.8.3. Diagnostic centers
13.8.4. Specialty Clinics and Rehab Centers
13.8.5. Research Institutes
13.8.6. Others
13.9. Asia Pacific Cardiopulmonary Disease Diagnostics and Treatment Market Value Share Analysis, by Country
13.10. Asia Pacific Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, by Country
13.10.1. China
13.10.2. India
13.10.3. Japan
13.10.4. ASEAN
13.10.5. Rest of Asia Pacific
13.11. Asia Pacific Cardiopulmonary Disease Diagnostics and Treatment Market Analysis, by Country
13.12. China Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By Type
13.12.1. Diagnostics
13.12.1.1. Electrocardiogram (ECG)
13.12.1.2. Holter monitoring
13.12.1.3. Echocardiogram
13.12.1.4. Stress test
13.12.1.5. Cardiac catheterization
13.12.1.6. Cardiac computerized tomography (CT) scan
13.12.1.7. Cardiac magnetic resonance imaging (MRI)
13.12.1.8. Single-photon emission computed tomography (SPECT)
13.12.1.9. Stress blood pressure monitors
13.12.1.10. Pulse oximeters
13.12.1.11. Spirometry
13.12.1.12. Treatment
13.12.2. Medication
13.12.2.1. Angiotensin-converting enzyme (ACE) inhibitors
13.12.2.2. Angiotensin II receptor blockers (ARBS)
13.12.2.3. Anticoagulants
13.12.2.4. Antiplatelet agents
13.12.2.5. Others
13.13. China Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By Disease Type
13.13.1. Cardiovascular diseases
13.13.1.1. Coronary artery disease
13.13.1.2. Angina pectoris
13.13.1.3. Myocardial infarction
13.13.1.4. Dysrhythmia
13.13.1.5. Hypertension
13.13.1.6. Others
13.13.2. Respiratory diseases
13.13.2.1. Influenza
13.13.2.2. Asthma
13.13.2.3. Bronchitis
13.13.2.4. Emphysema
13.13.2.5. Cystic fibrosis
13.13.2.6. Others
13.14. China Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By End User
13.14.1. Hospitals
13.14.2. Clinics
13.14.3. Diagnostic centers
13.14.4. Specialty Clinics and Rehab Centers
13.14.5. Research Institutes
13.14.6. Others
13.15. India Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By Type
13.15.1. Diagnostics
13.15.1.1. Electrocardiogram (ECG)
13.15.1.2. Holter monitoring
13.15.1.3. Echocardiogram
13.15.1.4. Stress test
13.15.1.5. Cardiac catheterization
13.15.1.6. Cardiac computerized tomography (CT) scan
13.15.1.7. Cardiac magnetic resonance imaging (MRI)
13.15.1.8. Single-photon emission computed tomography (SPECT)
13.15.1.9. Stress blood pressure monitors
13.15.1.10. Pulse oximeters
13.15.1.11. Spirometry
13.15.1.12. Treatment
13.15.2. Medication
13.15.2.1. Angiotensin-converting enzyme (ACE) inhibitors
13.15.2.2. Angiotensin II receptor blockers (ARBS)
13.15.2.3. Anticoagulants
13.15.2.4. Antiplatelet agents
13.15.2.5. Others
13.16. India Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By Disease Type
13.16.1. Cardiovascular diseases
13.16.1.1. Coronary artery disease
13.16.1.2. Angina pectoris
13.16.1.3. Myocardial infarction
13.16.1.4. Dysrhythmia
13.16.1.5. Hypertension
13.16.1.6. Others
13.16.2. Respiratory diseases
13.16.2.1. Influenza
13.16.2.2. Asthma
13.16.2.3. Bronchitis
13.16.2.4. Emphysema
13.16.2.5. Cystic fibrosis
13.16.2.6. Others
13.17. India Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By End User
13.17.1. Hospitals
13.17.2. Clinics
13.17.3. Diagnostic centers
13.17.4. Specialty Clinics and Rehab Centers
13.17.5. Research Institutes
13.17.6. Others
13.18. Japan Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By Type
13.18.1. Diagnostics
13.18.1.1. Electrocardiogram (ECG)
13.18.1.2. Holter monitoring
13.18.1.3. Echocardiogram
13.18.1.4. Stress test
13.18.1.5. Cardiac catheterization
13.18.1.6. Cardiac computerized tomography (CT) scan
13.18.1.7. Cardiac magnetic resonance imaging (MRI)
13.18.1.8. Single-photon emission computed tomography (SPECT)
13.18.1.9. Stress blood pressure monitors
13.18.1.10. Pulse oximeters
13.18.1.11. Spirometry
13.18.1.12. Treatment
13.18.2. Medication
13.18.2.1. Angiotensin-converting enzyme (ACE) inhibitors
13.18.2.2. Angiotensin II receptor blockers (ARBS)
13.18.2.3. Anticoagulants
13.18.2.4. Antiplatelet agents
13.18.2.5. Others
13.19. Japan Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By Disease Type
13.19.1. Cardiovascular diseases
13.19.1.1. Coronary artery disease
13.19.1.2. Angina pectoris
13.19.1.3. Myocardial infarction
13.19.1.4. Dysrhythmia
13.19.1.5. Hypertension
13.19.1.6. Others
13.19.2. Respiratory diseases
13.19.2.1. Influenza
13.19.2.2. Asthma
13.19.2.3. Bronchitis
13.19.2.4. Emphysema
13.19.2.5. Cystic fibrosis
13.19.2.6. Others
13.20. Japan Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By End User
13.20.1. Hospitals
13.20.2. Clinics
13.20.3. Diagnostic centers
13.20.4. Specialty Clinics and Rehab Centers
13.20.5. Research Institutes
13.20.6. Others
13.21. ASEAN Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By Type
13.21.1. Diagnostics
13.21.1.1. Electrocardiogram (ECG)
13.21.1.2. Holter monitoring
13.21.1.3. Echocardiogram
13.21.1.4. Stress test
13.21.1.5. Cardiac catheterization
13.21.1.6. Cardiac computerized tomography (CT) scan
13.21.1.7. Cardiac magnetic resonance imaging (MRI)
13.21.1.8. Single-photon emission computed tomography (SPECT)
13.21.1.9. Stress blood pressure monitors
13.21.1.10. Pulse oximeters
13.21.1.11. Spirometry
13.21.1.12. Treatment
13.21.2. Medication
13.21.2.1. Angiotensin-converting enzyme (ACE) inhibitors
13.21.2.2. Angiotensin II receptor blockers (ARBS)
13.21.2.3. Anticoagulants
13.21.2.4. Antiplatelet agents
13.21.2.5. Others
13.22. ASEAN Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By Disease Type
13.22.1. Cardiovascular diseases
13.22.1.1. Coronary artery disease
13.22.1.2. Angina pectoris
13.22.1.3. Myocardial infarction
13.22.1.4. Dysrhythmia
13.22.1.5. Hypertension
13.22.1.6. Others
13.22.2. Respiratory diseases
13.22.2.1. Influenza
13.22.2.2. Asthma
13.22.2.3. Bronchitis
13.22.2.4. Emphysema
13.22.2.5. Cystic fibrosis
13.22.2.6. Others
13.23. ASEAN Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By End User
13.23.1. Hospitals
13.23.2. Clinics
13.23.3. Diagnostic centers
13.23.4. Specialty Clinics and Rehab Centers
13.23.5. Research Institutes
13.23.6. Others
13.24. Rest of Asia Pacific Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By Type
13.24.1. Diagnostics
13.24.1.1. Electrocardiogram (ECG)
13.24.1.2. Holter monitoring
13.24.1.3. Echocardiogram
13.24.1.4. Stress test
13.24.1.5. Cardiac catheterization
13.24.1.6. Cardiac computerized tomography (CT) scan
13.24.1.7. Cardiac magnetic resonance imaging (MRI)
13.24.1.8. Single-photon emission computed tomography (SPECT)
13.24.1.9. Stress blood pressure monitors
13.24.1.10. Pulse oximeters
13.24.1.11. Spirometry
13.24.1.12. Treatment
13.24.2. Medication
13.24.2.1. Angiotensin-converting enzyme (ACE) inhibitors
13.24.2.2. Angiotensin II receptor blockers (ARBS)
13.24.2.3. Anticoagulants
13.24.2.4. Antiplatelet agents
13.24.2.5. Others
13.25. Rest of Asia Pacific Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By Disease Type
13.25.1. Cardiovascular diseases
13.25.1.1. Coronary artery disease
13.25.1.2. Angina pectoris
13.25.1.3. Myocardial infarction
13.25.1.4. Dysrhythmia
13.25.1.5. Hypertension
13.25.1.6. Others
13.25.2. Respiratory diseases
13.25.2.1. Influenza
13.25.2.2. Asthma
13.25.2.3. Bronchitis
13.25.2.4. Emphysema
13.25.2.5. Cystic fibrosis
13.25.2.6. Others
13.26. Rest of Asia Pacific Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By End User
13.26.1. Hospitals
13.26.2. Clinics
13.26.3. Diagnostic centers
13.26.4. Specialty Clinics and Rehab Centers
13.26.5. Research Institutes
13.26.6. Others
13.27. Asia Pacific Cardiopulmonary Disease Diagnostics and Treatment Market Attractiveness Analysis
13.27.1. By Type
13.27.2. By Disease Type
13.27.3. By End User
13.28. PEST Analysis
13.29. Key Trends
13.30. Key Developments
14. Middle East & Africa Cardiopulmonary Disease Diagnostics and Treatment Market Analysis
14.1. Key Findings
14.2. Middle East & Africa Cardiopulmonary Disease Diagnostics and Treatment Market Overview
14.3. Middle East & Africa Cardiopulmonary Disease Diagnostics and Treatment Market Value Share Analysis, By Type
14.4. Middle East & Africa Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By Type
14.4.1. Diagnostics
14.4.1.1. Electrocardiogram (ECG)
14.4.1.2. Holter monitoring
14.4.1.3. Echocardiogram
14.4.1.4. Stress test
14.4.1.5. Cardiac catheterization
14.4.1.6. Cardiac computerized tomography (CT) scan
14.4.1.7. Cardiac magnetic resonance imaging (MRI)
14.4.1.8. Single-photon emission computed tomography (SPECT)
14.4.1.9. Stress blood pressure monitors
14.4.1.10. Pulse oximeters
14.4.1.11. Spirometry
14.4.1.12. Treatment
14.4.2. Medication
14.4.2.1. Angiotensin-converting enzyme (ACE) inhibitors
14.4.2.2. Angiotensin II receptor blockers (ARBS)
14.4.2.3. Anticoagulants
14.4.2.4. Antiplatelet agents
14.4.2.5. Others
14.5. Middle East & Africa Cardiopulmonary Disease Diagnostics and Treatment Market Value Share Analysis, By Disease Type
14.6. Middle East & Africa Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By Disease Type
14.6.1. Cardiovascular diseases
14.6.1.1. Coronary artery disease
14.6.1.2. Angina pectoris
14.6.1.3. Myocardial infarction
14.6.1.4. Dysrhythmia
14.6.1.5. Hypertension
14.6.1.6. Others
14.6.2. Respiratory diseases
14.6.2.1. Influenza
14.6.2.2. Asthma
14.6.2.3. Bronchitis
14.6.2.4. Emphysema
14.6.2.5. Cystic fibrosis
14.6.2.6. Others
14.7. Middle East & Africa Cardiopulmonary Disease Diagnostics and Treatment Market Value Share Analysis, By End User
14.8. Middle East & Africa Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By End User
14.8.1. Hospitals
14.8.2. Clinics
14.8.3. Diagnostic centers
14.8.4. Specialty Clinics and Rehab Centers
14.8.5. Research Institutes
14.8.6. Others
14.9. Middle East & Africa Cardiopulmonary Disease Diagnostics and Treatment Market Value Share Analysis, by Country
14.10. Middle East & Africa Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, by Country
14.10.1. GCC
14.10.2. South Africa
14.10.3. Rest of Middle East & Africa
14.11. Middle East & Africa Cardiopulmonary Disease Diagnostics and Treatment Market Analysis, by Country
14.12. GCC Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By Type
14.12.1. Diagnostics
14.12.1.1. Electrocardiogram (ECG)
14.12.1.2. Holter monitoring
14.12.1.3. Echocardiogram
14.12.1.4. Stress test
14.12.1.5. Cardiac catheterization
14.12.1.6. Cardiac computerized tomography (CT) scan
14.12.1.7. Cardiac magnetic resonance imaging (MRI)
14.12.1.8. Single-photon emission computed tomography (SPECT)
14.12.1.9. Stress blood pressure monitors
14.12.1.10. Pulse oximeters
14.12.1.11. Spirometry
14.12.1.12. Treatment
14.12.2. Medication
14.12.2.1. Angiotensin-converting enzyme (ACE) inhibitors
14.12.2.2. Angiotensin II receptor blockers (ARBS)
14.12.2.3. Anticoagulants
14.12.2.4. Antiplatelet agents
14.12.2.5. Others
14.13. GCC Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By Disease Type
14.13.1. Cardiovascular diseases
14.13.1.1. Coronary artery disease
14.13.1.2. Angina pectoris
14.13.1.3. Myocardial infarction
14.13.1.4. Dysrhythmia
14.13.1.5. Hypertension
14.13.1.6. Others
14.13.2. Respiratory diseases
14.13.2.1. Influenza
14.13.2.2. Asthma
14.13.2.3. Bronchitis
14.13.2.4. Emphysema
14.13.2.5. Cystic fibrosis
14.13.2.6. Others
14.14. GCC Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By End User
14.14.1. Hospitals
14.14.2. Clinics
14.14.3. Diagnostic centers
14.14.4. Specialty Clinics and Rehab Centers
14.14.5. Research Institutes
14.14.6. Others
14.15. South Africa Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By Type
14.15.1. Diagnostics
14.15.1.1. Electrocardiogram (ECG)
14.15.1.2. Holter monitoring
14.15.1.3. Echocardiogram
14.15.1.4. Stress test
14.15.1.5. Cardiac catheterization
14.15.1.6. Cardiac computerized tomography (CT) scan
14.15.1.7. Cardiac magnetic resonance imaging (MRI)
14.15.1.8. Single-photon emission computed tomography (SPECT)
14.15.1.9. Stress blood pressure monitors
14.15.1.10. Pulse oximeters
14.15.1.11. Spirometry
14.15.1.12. Treatment
14.15.2. Medication
14.15.2.1. Angiotensin-converting enzyme (ACE) inhibitors
14.15.2.2. Angiotensin II receptor blockers (ARBS)
14.15.2.3. Anticoagulants
14.15.2.4. Antiplatelet agents
14.15.2.5. Others
14.16. South Africa Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By Disease Type
14.16.1. Cardiovascular diseases
14.16.1.1. Coronary artery disease
14.16.1.2. Angina pectoris
14.16.1.3. Myocardial infarction
14.16.1.4. Dysrhythmia
14.16.1.5. Hypertension
14.16.1.6. Others
14.16.2. Respiratory diseases
14.16.2.1. Influenza
14.16.2.2. Asthma
14.16.2.3. Bronchitis
14.16.2.4. Emphysema
14.16.2.5. Cystic fibrosis
14.16.2.6. Others
14.17. South Africa Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By End User
14.17.1. Hospitals
14.17.2. Clinics
14.17.3. Diagnostic centers
14.17.4. Specialty Clinics and Rehab Centers
14.17.5. Research Institutes
14.17.6. Others
14.18. Rest of Middle East & Africa Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By Type
14.18.1. Diagnostics
14.18.1.1. Electrocardiogram (ECG)
14.18.1.2. Holter monitoring
14.18.1.3. Echocardiogram
14.18.1.4. Stress test
14.18.1.5. Cardiac catheterization
14.18.1.6. Cardiac computerized tomography (CT) scan
14.18.1.7. Cardiac magnetic resonance imaging (MRI)
14.18.1.8. Single-photon emission computed tomography (SPECT)
14.18.1.9. Stress blood pressure monitors
14.18.1.10. Pulse oximeters
14.18.1.11. Spirometry
14.18.1.12. Treatment
14.18.2. Medication
14.18.2.1. Angiotensin-converting enzyme (ACE) inhibitors
14.18.2.2. Angiotensin II receptor blockers (ARBS)
14.18.2.3. Anticoagulants
14.18.2.4. Antiplatelet agents
14.18.2.5. Others
14.19. Rest of Middle East & Africa Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By Disease Type
14.19.1. Cardiovascular diseases
14.19.1.1. Coronary artery disease
14.19.1.2. Angina pectoris
14.19.1.3. Myocardial infarction
14.19.1.4. Dysrhythmia
14.19.1.5. Hypertension
14.19.1.6. Others
14.19.2. Respiratory diseases
14.19.2.1. Influenza
14.19.2.2. Asthma
14.19.2.3. Bronchitis
14.19.2.4. Emphysema
14.19.2.5. Cystic fibrosis
14.19.2.6. Others
14.20. Middle East & Africa Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By End User
14.20.1. Hospitals
14.20.2. Clinics
14.20.3. Diagnostic centers
14.20.4. Specialty Clinics and Rehab Centers
14.20.5. Research Institutes
14.20.6. Others
14.21. Middle East & Africa Cardiopulmonary Disease Diagnostics and Treatment Market Attractiveness Analysis
14.21.1. By Type
14.21.2. By Disease Type
14.21.3. By End User
14.22. PEST Analysis
14.23. Key Trends
14.24. Key Developments
15. South America Cardiopulmonary Disease Diagnostics and Treatment Market Analysis
15.1. Key Findings
15.2. South America Cardiopulmonary Disease Diagnostics and Treatment Market Overview
15.3. South America Cardiopulmonary Disease Diagnostics and Treatment Market Value Share Analysis, By Type
15.4. South America Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By Type
15.4.1. Diagnostics
15.4.1.1. Electrocardiogram (ECG)
15.4.1.2. Holter monitoring
15.4.1.3. Echocardiogram
15.4.1.4. Stress test
15.4.1.5. Cardiac catheterization
15.4.1.6. Cardiac computerized tomography (CT) scan
15.4.1.7. Cardiac magnetic resonance imaging (MRI)
15.4.1.8. Single-photon emission computed tomography (SPECT)
15.4.1.9. Stress blood pressure monitors
15.4.1.10. Pulse oximeters
15.4.1.11. Spirometry
15.4.1.12. Treatment
15.4.2. Medication
15.4.2.1. Angiotensin-converting enzyme (ACE) inhibitors
15.4.2.2. Angiotensin II receptor blockers (ARBS)
15.4.2.3. Anticoagulants
15.4.2.4. Antiplatelet agents
15.4.2.5. Others
15.5. South America Cardiopulmonary Disease Diagnostics and Treatment Market Value Share Analysis, By Disease Type
15.6. South America Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By Disease Type
15.6.1. Cardiovascular diseases
15.6.1.1. Coronary artery disease
15.6.1.2. Angina pectoris
15.6.1.3. Myocardial infarction
15.6.1.4. Dysrhythmia
15.6.1.5. Hypertension
15.6.1.6. Others
15.6.2. Respiratory diseases
15.6.2.1. Influenza
15.6.2.2. Asthma
15.6.2.3. Bronchitis
15.6.2.4. Emphysema
15.6.2.5. Cystic fibrosis
15.6.2.6. Others
15.7. South America Cardiopulmonary Disease Diagnostics and Treatment Market Value Share Analysis, By End User
15.8. South America Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By End User
15.8.1. Hospitals
15.8.2. Clinics
15.8.3. Diagnostic centers
15.8.4. Specialty Clinics and Rehab Centers
15.8.5. Research Institutes
15.8.6. Others
15.9. South America Cardiopulmonary Disease Diagnostics and Treatment Market Value Share Analysis, by Country
15.10. South America Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, by Country
15.10.1. Brazil
15.10.2. Mexico
15.10.3. Rest of South America
15.11. South America Cardiopulmonary Disease Diagnostics and Treatment Market Analysis, by Country
15.12. Brazil Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By Type
15.12.1. Diagnostics
15.12.1.1. Electrocardiogram (ECG)
15.12.1.2. Holter monitoring
15.12.1.3. Echocardiogram
15.12.1.4. Stress test
15.12.1.5. Cardiac catheterization
15.12.1.6. Cardiac computerized tomography (CT) scan
15.12.1.7. Cardiac magnetic resonance imaging (MRI)
15.12.1.8. Single-photon emission computed tomography (SPECT)
15.12.1.9. Stress blood pressure monitors
15.12.1.10. Pulse oximeters
15.12.1.11. Spirometry
15.12.1.12. Treatment
15.12.2. Medication
15.12.2.1. Angiotensin-converting enzyme (ACE) inhibitors
15.12.2.2. Angiotensin II receptor blockers (ARBS)
15.12.2.3. Anticoagulants
15.12.2.4. Antiplatelet agents
15.12.2.5. Others
15.13. Brazil Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By Disease Type
15.13.1. Cardiovascular diseases
15.13.1.1. Coronary artery disease
15.13.1.2. Angina pectoris
15.13.1.3. Myocardial infarction
15.13.1.4. Dysrhythmia
15.13.1.5. Hypertension
15.13.1.6. Others
15.13.2. Respiratory diseases
15.13.2.1. Influenza
15.13.2.2. Asthma
15.13.2.3. Bronchitis
15.13.2.4. Emphysema
15.13.2.5. Cystic fibrosis
15.13.2.6. Others
15.14. Brazil Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By End User
15.14.1. Hospitals
15.14.2. Clinics
15.14.3. Diagnostic centers
15.14.4. Specialty Clinics and Rehab Centers
15.14.5. Research Institutes
15.14.6. Others
15.15. Mexico Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By Type
15.15.1. Diagnostics
15.15.1.1. Electrocardiogram (ECG)
15.15.1.2. Holter monitoring
15.15.1.3. Echocardiogram
15.15.1.4. Stress test
15.15.1.5. Cardiac catheterization
15.15.1.6. Cardiac computerized tomography (CT) scan
15.15.1.7. Cardiac magnetic resonance imaging (MRI)
15.15.1.8. Single-photon emission computed tomography (SPECT)
15.15.1.9. Stress blood pressure monitors
15.15.1.10. Pulse oximeters
15.15.1.11. Spirometry
15.15.1.12. Treatment
15.15.2. Medication
15.15.2.1. Angiotensin-converting enzyme (ACE) inhibitors
15.15.2.2. Angiotensin II receptor blockers (ARBS)
15.15.2.3. Anticoagulants
15.15.2.4. Antiplatelet agents
15.15.2.5. Others
15.16. Mexico Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By Disease Type
15.16.1. Cardiovascular diseases
15.16.1.1. Coronary artery disease
15.16.1.2. Angina pectoris
15.16.1.3. Myocardial infarction
15.16.1.4. Dysrhythmia
15.16.1.5. Hypertension
15.16.1.6. Others
15.16.2. Respiratory diseases
15.16.2.1. Influenza
15.16.2.2. Asthma
15.16.2.3. Bronchitis
15.16.2.4. Emphysema
15.16.2.5. Cystic fibrosis
15.16.2.6. Others
15.17. Mexico Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By End User
15.17.1. Hospitals
15.17.2. Clinics
15.17.3. Diagnostic centers
15.17.4. Specialty Clinics and Rehab Centers
15.17.5. Research Institutes
15.17.6. Others
15.18. Rest of South America Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By Type
15.18.1. Diagnostics
15.18.1.1. Electrocardiogram (ECG)
15.18.1.2. Holter monitoring
15.18.1.3. Echocardiogram
15.18.1.4. Stress test
15.18.1.5. Cardiac catheterization
15.18.1.6. Cardiac computerized tomography (CT) scan
15.18.1.7. Cardiac magnetic resonance imaging (MRI)
15.18.1.8. Single-photon emission computed tomography (SPECT)
15.18.1.9. Stress blood pressure monitors
15.18.1.10. Pulse oximeters
15.18.1.11. Spirometry
15.18.1.12. Treatment
15.18.2. Medication
15.18.2.1. Angiotensin-converting enzyme (ACE) inhibitors
15.18.2.2. Angiotensin II receptor blockers (ARBS)
15.18.2.3. Anticoagulants
15.18.2.4. Antiplatelet agents
15.18.2.5. Others
15.19. Rest of South America Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By Disease Type
15.19.1. Cardiovascular diseases
15.19.1.1. Coronary artery disease
15.19.1.2. Angina pectoris
15.19.1.3. Myocardial infarction
15.19.1.4. Dysrhythmia
15.19.1.5. Hypertension
15.19.1.6. Others
15.19.2. Respiratory diseases
15.19.2.1. Influenza
15.19.2.2. Asthma
15.19.2.3. Bronchitis
15.19.2.4. Emphysema
15.19.2.5. Cystic fibrosis
15.19.2.6. Others
15.20. Rest of South America Cardiopulmonary Disease Diagnostics and Treatment Market Forecast, By End User
15.20.1. Hospitals
15.20.2. Clinics
15.20.3. Diagnostic centers
15.20.4. Specialty Clinics and Rehab Centers
15.20.5. Research Institutes
15.20.6. Others
15.21. South America Cardiopulmonary Disease Diagnostics and Treatment Market Attractiveness Analysis
15.21.1. By Type
15.21.2. By Disease Type
15.21.3. By End User
15.22. PEST Analysis
15.23. Key Trends
15.24. Key Developments
16. Company Profiles
16.1. Market Share Analysis, by Company
16.2. Competition Matrix
16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment
16.2.2. New Product Launches and Product Enhancements
16.2.3. Market Consolidation
16.2.3.1. M&A by Regions, Investment and Applications
16.2.3.2. M&A Key Players, Forward Integration and Backward Integration
16.3. Company Profiles: Key Players
16.3.1. Cardinal Health
16.3.2 Cosmed Medical
16.3.3 GE Healthcare
16.3.4 Halma plc
16.3.5 Hill-Rom Holdings, Inc.
16.3.6 Koninklijke Philips N.V.
16.3.7 MGC Diagnostics Corporation
16.3.8 Nihon Kohden Corporation
16.3.9 Schiller AG
16.3.10 Masimo Corporation
16.3.11 Vyaire Medical Inc.
16.3.12 Medtronic plc
16.3.13 Boston Scientific Corporation
16.3.14 LivaNova PLC
16.3.15 Siemens Healthineers
16.3.16 St. Jude Medical, Inc.
16.3.17 Stryker Corporation
16.3.18 Baxter International Inc.
16.3.19 Abbott Laboratories
16.3.20 Becton Dickinson
17. Primary Key Insights